KPMG Women's PGA 2025: Minjee Lee wins third career major championship
A champion was crowned in Frisco on Sunday as LPGA pros competed in the final round 2025 KPMG Women's PGA Championship, the third major in 2025 for the women.
Minjee Lee and Jeeno Thitikul were in the final pairing but it didn't shape up to be a Sunday duel as Lee was over par but able to fend off all challengers at a golf course that the No. 1 player in the world called "almost impossible" at times.
Advertisement
Golfweek provided updates, scores and highlights from the 2025 KPMG Women's PGA Championship:
KPMG Women's PGA 2025 live leaderboard
Here's a look at the top of the final 2025 KPMG Women's PGA Championship leaderboard.
Minjee Lee wins 2025 KPMG Women's PGA for third career major
Lee was 2 over in her final round but she was able to fend off all challengers during Sunday's final round. Auston Kim and Chanettee Wannasean each posted 4-under 68s but were only able to get to 1 under.
Lee did card three birdies but also posted five bogeys, but it was enough during a windy week in Frisco, Texas. She is the third Aussie to win three LPGA majors.
Lee is the first Australian to win the KPMG Women's PGA Championship since Hannah Green in 2019. She's the third Australian to win three or more major championships, joining Karrie Webb and Jan Stephenson. Lee is now the 31st player in LPGA history to win three or more major championships.
Minjee Lee earns $1.8 million for KPMG victory
Earlier in the week tournament officials announced a purse increase to $12 million, matching the U.S. Women's Open for the highest prize fund on tour. For perspective, just four years ago the KPMG purse was $4.5 million. Lee earned $1.8 million for her victory.
Advertisement
At the 2022 U.S. Women's Open, she earned the biggest paycheck in women's golf history to date when she earned $1.8 million. (Later that same season, the winner of CME Group Tour Championship in November earned $2 million.)
-Beth Ann Nichols
Minjee Lee poses with the trophy after winning the 2025 KPMG Women's PGA Championship.
Minjee Lee posts back-to-back birdies down the stretch
Lee is still 1 over overall in her final round but she has made consecutive birdies on Nos. 13 and 14 to get to 5 under and take a four-shot lead down the stretch in Frisco. Auston Kim has posted a final-round 68 and is the clubhouse leader at 1 under. Lee won the 2022 U.S. Women's Open and the 2021 Amundi Evian Championship. A KPMG victory would be her third major title and 11th LPGA win.
Maja Stark breaks putter in frustration
Three weeks after Maja Stark hoisted a trophy on a major championship Sunday, she broke her putter at the KPMG Women's PGA Championship. As the wind and heat made for an unrelenting cauldron of pressure, Stark's frustrations boiled over late in the final round.
Advertisement
-Beth Ann Nichols
Early bogeys not derailing Minjee Lee
Minjee Lee has bogeyed three of the first six holes but still leads the KPMG by two. The two-time major winner began the day four strokes ahead of Jeeno Thitikul. In the past 15 years, eight players have held an advantage of four strokes or more entering the final round of an LPGA major and all but one went on to win. Jeongeun Lee6 was the lone exception after leading the 2021 Evian by five.
Minjee Lee waves to the gallery after putting out on the second hole during the final round of the 2025 KPMG Women's PGA Championship.
-Beth Ann Nichols
Minjee Lee now the lone golfer under par at the KPMG
After Jeeno Thitikul bogeyed two of her first three holes, Minjee Lee became the lone golfer in Frisco in red numbers. Lee is 1 over herself after three holes but at 5 under, she holds a five-shot lead.
Leaders are on the course
Just after 9 a.m. ET, Lee and Thitikul took to the course to start their final round. Lee parred the par-5 opening hole while Thitikul bogeyed it, opening a five-shot lead for Lee.
What will the weather be like Sunday at the KPMG Women's PGA?
Players have dealt with brutal heat and strong winds to go along with painfully long rounds during this week's KPMG. Unfortunately, it's going to be another scorcher on Sunday.
Advertisement
High temperatures will reach the mid-90s, with heat index creeping close to 100. Steady winds will be blowing at 15 mph from the south and could gust up to 30-40 mph at times.
How much money does the winner get at the 2025 KPMG Women's PGA?
The total purse for this year's KPMG Women's PGA is a record-breaking $12 million, with $1.8 million going to the winner.
How to watch the final round of the KPMG Women's PGA
11 a.m. - 3 p.m. streaming on Peacock
3 p.m. - 6 p.m. on NBC
This article originally appeared on Golfweek: Minjee Lee wins KPMG Women's PGA 2025 for third career LPGA major
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Forbes
39 minutes ago
- Forbes
Is Lululemon A Bargain At $230?
AUSTIN, TEXAS - JUNE 17: A Lululemon retail store is seen in the Barton Creek Square mall on June ... More 17, 2025 in Austin, Texas. Retail sales declined 0.9% in May according to a recent report conducted by the U.S. Commerce Department. (Photo by) Lululemon stock (NASDAQ: LULU) has lost 30% since announcing Q1 2025 earnings and is currently priced at approximately $229, a 40% drop year-to-date, significantly trailing the S&P 500's 2% increase. However, this selloff appears to be driven more by sentiment rather than being fundamentally warranted. The company reported strong results: revenue increased by 7% to $2.37 billion, and EPS grew by 2% year-over-year to $2.60, slightly surpassing expectations. Nevertheless, investors were focused on a modest 1% same-store sales increase and a reduced full-year forecast, partly affected by tariff concerns. Even so, Lululemon's strong financial health indicates that the market may be overreacting. For a brand often seen as premium, Lululemon stock is now behaving like a value stock. With a trailing earnings multiple of just 15x, it trades substantially below both its historical average and the broader market's 27x. Its 21x price-to-free-cash-flow ratio is only marginally above the S&P 500 average — but for a company delivering superior margins, growth, and returns on capital, that premium is warranted. In comparison to Nike, Lululemon appears particularly attractive: it features a lower P/E and a more robust free cash flow profile. With a market cap of $27 billion and trailing free cash flow of $1.6 billion, LULU achieves a cash flow yield of nearly 6% — a figure characteristic of long-term compounders rather than volatile retail stocks. For investors looking for less volatility compared to individual stocks, the Trefis High Quality portfolio offers an alternative, having outperformed the S&P 500 and generated returns greater than 91% since its inception. A Growth Engine with Elite Financials Lululemon continues to be a growth powerhouse. Over the last three years, it has achieved a revenue CAGR of 19%, surpassing the S&P 500's 5.5% by more than three times. In the past 12 months alone, sales increased by 10% to nearly $11 billion, supported by a growing global presence and brand equity. Regarding profitability, the company reported a 23.4% operating margin and an 18.8% operating cash flow margin over the past four quarters, both significantly above the market average. Its 16.8% net income margin further solidifies its reputation as one of the most operationally efficient players in the retail sector. Financial Strength Few Can Compete With Lululemon's balance sheet is in excellent condition. With a debt-to-equity ratio of only 6.0%—well below the S&P 500's 19.4%—and $1.3 billion in cash representing 17.8% of its total assets, the company enjoys low leverage and high liquidity. It is well-positioned to invest, expand, or endure downturns comfortably. The Warning: This Journey Isn't Always Smooth There's no denying it: Lululemon has experienced significant declines during market corrections. It dropped 46% during the 2022 downturn (compared to the S&P's 25%), plummeted 47% in the early 2020 Covid shock (versus 34%), and was severely impacted during the 2008 crash, falling 92% (in contrast to 57%). Investors must recognize that with LULU, solid fundamentals do not always protect against sharp sentiment fluctuations. Our dashboard How Low Can Stocks Go During A Market Crash captures how major stocks performed during and after the last six market crashes. Invest with a Touch of Volatility Lululemon ticks nearly every box—solid growth, noteworthy profitability, and a strong balance sheet. Its only significant downside? Vulnerability to market fluctuations. While Q1 revealed mixed results and cautious guidance, the long-term fundamentals remain firmly established. Investing in a specific stock carries risks. You might also consider the Trefis Reinforced Value (RV) Portfolio, which has outpaced its all-cap stocks benchmark (a combination of the S&P 500, S&P mid-cap, and Russell 2000 benchmark indices) to deliver strong returns for investors. Why is that? The quarterly rebalanced mix of large-, mid-, and small-cap RV Portfolio stocks made it a responsive way to maximize benefits during favorable market conditions while minimizing losses when markets decline, as outlined in RV Portfolio performance metrics.
Yahoo
an hour ago
- Yahoo
Elon Musk Announces Launch of New Business Venture
It's official: Tesla is in the robotaxi industry. After revealing that Tesla would begin rolling out autonomous cabs this year, Tesla co-founder and CEO Elon Musk announced the company is officially launching it's robotaxi service on Sunday, June 22. In a post on X, Musk revealed that the robotaxis will debut in Austin, Texas, and customers will pay a flat fee of $4.20. "The (Tesla AI) robotaxi launch begins in Austin this afternoon with customers paying a $4.20 flat fee!" Musk exclaimed. With the launch, Tesla will now look to make up ground on Waymo, which is the current king of the industry. Waymo claims to have taken 10 million paid rides in all and services several major cities, including Austin, where Tesla is debuting on Sunday. Meanwhile, Amazon is also expected to get into the industry this year. The mega corporation spent $1.2 billion to acquire Zoox about five years ago and it has since built a plant in Silicon Valley that is expected to produce 10,000 robotaxis per year. However, Amazon and Zoox are not as far along as Waymo and Tesla, with the duo set to begin its service in Las Vegas later this year, and then in San Francisco next Musk Announces Launch of New Business Venture first appeared on Men's Journal on Jun 22, 2025 Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
an hour ago
- Yahoo
Illuccix Approved in U.S. for Patient Selection for Pre-Taxane RLT
MELBOURNE, Australia and INDIANAPOLIS, June 23, 2025 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, 'Telix', 'the Company') today announces that the United States (U.S.) Food and Drug Administration (FDA) has approved a label expansion for Illuccix® (kit for the preparation of gallium Ga-68 gozetotide, for injection) to include patient selection for radioligand therapy (RLT) in the pre-taxane setting. The update applies to Illuccix's third indication, for selection of patients who are indicated for PSMA1-directed therapy as described in the Prescribing Information of the therapeutic products. The label expansion follows the FDA's approval of an expanded label for Pluvicto®2 (lutetium Lu177 vipivotide tetraxetan) for use in metastatic castration-resistant prostate cancer (mCRPC) patients after treatment with androgen receptor pathway inhibitor (ARPI) therapy and before chemotherapy3. With RLT now approved for use earlier in the patient journey, the clinical utilization of Illuccix® is expected to increase by at least 20,000 scans annually4. Scott T. Tagawa, MD, a genitourinary (GU) oncologist in New York said, 'It is pleasing to see the ability to use gallium-68 PSMA-PET for patient selection expanded. This empowers clinicians to make more informed, personalized decisions earlier in the disease course and access life-prolonging targeted radionuclide therapy for more patients with prostate cancer.' Kevin Richardson, Chief Executive Officer, Precision Medicine, Telix, said, 'We're pleased that the U.S. label for Illuccix has been expanded to support patient selection for RLT in the pre-taxane setting, aligning with the evolving treatment landscape. PSMA-PET imaging has become a standard of care in the detection and management of prostate cancer. With this update, patients can now benefit from the high diagnostic accuracy of Illuccix to identify those most likely to respond to PSMA-targeted therapy, even earlier in their treatment journey.' INDICATIONS AND USAGE Illuccix, after radiolabeling with Ga 68, is for positron emission tomography (PET) of prostate-specific membrane antigen (PSMA) positive lesions in men with prostate cancer: With suspected metastasis who are candidates for initial definitive therapy With suspected recurrence based on elevated serum prostate-specific antigen (PSA) level For selection of patients who are indicated for PSMA-directed therapy as described in the Prescribing Information of the therapeutic products IMPORTANT SAFETY INFORMATIONWARNINGS AND PRECAUTIONS Risk for MisinterpretationImage interpretation errors can occur with Illuccix PET. A negative image does not rule out the presence of prostate cancer, and a positive image does not confirm the presence of prostate cancer. Gallium Ga 68 gozetotide uptake is not specific for prostate cancer and may occur with other types of cancer as well as non-malignant processes such as Paget's disease, fibrous dysplasia, and osteophytosis. Clinical correlation, which may include histopathological evaluation of the suspected prostate cancer site, is recommended. Imaging Prior to Initial Definitive or Suspected Recurrence TherapyThe performance of Illuccix for imaging of biochemically recurrent prostate cancer seems to be affected by serum PSA levels and by site of disease. The performance of Illuccix for imaging of metastatic pelvic lymph nodes prior to initial definitive therapy seems to be affected by Gleason score. Radiation RisksGallium Ga 68 gozetotide contributes to a patient's overall long-term cumulative radiation exposure. Long-term cumulative radiation exposure is associated with an increased risk for cancer. Ensure safe handling to minimize radiation exposure to the patient and healthcare providers. Advise patients to hydrate before and after administration and to void frequently after administration. ADVERSE REACTIONSThe safety of gallium Ga 68 gozetotide was evaluated in 960 patients in the PSMA-PreRP and PSMA-BCR studies, each receiving one dose of gallium Ga 68 gozetotide. The average injected activity was 188.7 ± 40.7 MBq (5.1 ± 1.1 mCi). The most commonly reported adverse reactions were nausea, diarrhea, and dizziness, occurring at a rate of <1%.In the VISION study, 1003 patients received one dose of gallium Ga 68 gozetotide intravenously with the amount of radioactivity 167.1 ± 23.1 MBq (4.52 ± 0.62 mCi). Adverse reactions occurring at ≥0.5% in patients with metastatic prostate cancer who received gallium Ga 68 gozetotide injection in the clinical study were fatigue (1.2%), nausea (0.8%), constipation (0.5%), and vomiting (0.5%). Adverse reactions occurring at a rate of < 0.5% in the VISION study were diarrhea, dry mouth, injection site reactions, including injection site hematoma and injection site warmth and chills. DRUG INTERACTIONSAndrogen deprivation therapy and other therapies targeting the androgen pathwayAndrogen deprivation therapy (ADT) and other therapies targeting the androgen pathway, such as androgen receptor antagonists, can result in changes in uptake of gallium Ga 68 gozetotide in prostate cancer. The effect of these therapies on performance of gallium Ga 68 gozetotide PET has not been established. Please note that this information is not see the Full Prescribing Information . You are encouraged to report suspected adverse reactions of prescription drugs to the FDA. Visit MedWatch at or call 1-800-FDA-1088. You may also report adverse reactions to Telix by calling 1-844-455-8638 or emailing: pharmacovigilance@ Dr. Tagawa has served as a paid consultant to Telix and his institution has received research funding. Telix Investor Relations Ms. Kyahn WilliamsonTelix Pharmaceuticals LimitedSVP Investor Relations and Corporate CommunicationsEmail: Telix Media Relations (U.S.) Eliza Schleifstein ES Media Relations Email: eliza@ Phone: 917-763-8106 About Telix Pharmaceuticals Limited Telix is a biopharmaceutical company focused on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals and associated medical technologies. Telix is headquartered in Melbourne, Australia, with international operations in the United States, Brazil, Canada, Europe (Belgium and Switzerland), and Japan. Telix is developing a portfolio of clinical and commercial stage products that aims to address significant unmet medical needs in oncology and rare diseases. Telix is listed on the Australian Securities Exchange (ASX: TLX) and the Nasdaq Global Select Market (NASDAQ: TLX). Illuccix® (kit for the preparation of gallium-68 (68Ga) gozetotide injection), Telix's first generation PSMA-PET imaging agent, is approved and commercially available in multiple countries globally. Gozellix® (kit for the preparation of gallium-68 (68Ga) gozetotide injection) has been approved by the U.S. FDA5. Visit for further information about Telix, including details of the latest share price, ASX and SEC filings, investor and analyst presentations, news releases, event details and other publications that may be of interest. You can also follow Telix on LinkedIn, X and Facebook. Legal Notices You should read this announcement together with our risk factors, as disclosed in our most recently filed reports with the Australian Securities Exchange (ASX), U.S. Securities and Exchange Commission (SEC), including our Annual Report on Form 20-F filed with the SEC, or on our website. The information contained in this announcement is not intended to be an offer for subscription, invitation or recommendation with respect to securities of Telix Pharmaceuticals Limited (Telix) in any jurisdiction, including the United States. The information and opinions contained in this announcement are subject to change without notification. To the maximum extent permitted by law, Telix disclaims any obligation or undertaking to update or revise any information or opinions contained in this announcement, including any forward-looking statements (as referred to below), whether as a result of new information, future developments, a change in expectations or assumptions, or otherwise. No representation or warranty, express or implied, is made in relation to the accuracy or completeness of the information contained or opinions expressed in the course of this announcement. This announcement may contain forward-looking statements, including within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, that relate to anticipated future events, financial performance, plans, strategies or business developments. Forward-looking statements can generally be identified by the use of words such as 'may', 'expect', 'intend', 'plan', 'estimate', 'anticipate', 'believe', 'outlook', 'forecast' and 'guidance', or the negative of these words or other similar terms or expressions. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to differ materially from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. Forward-looking statements are based on Telix's good-faith assumptions as to the financial, market, regulatory and other risks and considerations that exist and affect Telix's business and operations in the future and there can be no assurance that any of the assumptions will prove to be correct. In the context of Telix's business, forward-looking statements may include, but are not limited to, statements about: the initiation, timing, progress and results of Telix's preclinical and clinical trials, and Telix's research and development programs; Telix's ability to advance product candidates into, enrol and successfully complete, clinical studies, including multi-national clinical trials; the timing or likelihood of regulatory filings and approvals for Telix's product candidates, manufacturing activities and product marketing activities; Telix's sales, marketing and distribution and manufacturing capabilities and strategies; the commercialization of Telix's product candidates, if or when they have been approved; Telix's ability to obtain an adequate supply of raw materials at reasonable costs for its products and product candidates; estimates of Telix's expenses, future revenues and capital requirements; Telix's financial performance; developments relating to Telix's competitors and industry; the anticipated impact of U.S. and foreign tariffs and other macroeconomic conditions on Telix's business; and the pricing and reimbursement of Telix's product candidates, if and after they have been approved. Telix's actual results, performance or achievements may be materially different from those which may be expressed or implied by such statements, and the differences may be adverse. Accordingly, you should not place undue reliance on these forward-looking statements. ©2025 Telix Pharmaceuticals Limited. Telix Pharmaceuticals®, Telix Group company, and Telix product names and logos are trademarks of Telix Pharmaceuticals Limited and its affiliates – all rights reserved. Trademark registration status may vary from country to country. _________________________1 Prostate-specific membrane antigen2 Pluvicto is a registered trademark of Novartis AG and/or its affiliates.3 28 March 2025, FDA Statement: for patients who have been treated with ARPI therapy and are considered appropriate to delay taxane-based chemotherapy.4 Based on licensed indication for Pluvicto in mCRPC patients who have been treated with androgen receptor (AR) pathway inhibition.5 Telix ASX disclosure 21 March 2025.
